This is highly speculative because: Oral bioavailability differs between species Route of administration affects systemic exposure Species differences in peptide metabolism and clearance are unknown Current Practice Patterns Current practice patterns from unregulated sources typically involve: Subcutaneous injection: 0.25-0.5 mg once or twice daily, administered near injection sites for localized effects or abdominally for systemic distribution
Andrew Huberman explained the mechanism on Rogan's podcast: BPC-157 acts like a "repair signal" that encourages fibroblasts, the cells that build connective tissue, to migrate to injury sites and start rebuilding
If you have time, might be worth finding the local B12 deficiency guidelines for your ICB (Integrated Care Board) or Health Board
We review your history and check your B12 level so treatment is based on your actual numbers, not a guess
The number of sprays per nostril and frequency of administration may vary, necessitating adherence to the specific guidelines
This keeps quality consistent and costs under control